1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Neuropathy - Pipeline Review, H2 2020, provides an overview of the Diabetic Neuropathy (Metabolic Disorders) pipeline landscape.
Diabetic neuropathy, a common complication of diabetes, is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning and pain. The predisposing factors are obesity, hypertension, high lipid and sugar levels, smoking, etc. It may be managed by medication and dietary modification.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Diabetic Neuropathy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Diabetic Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diabetic Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 12, 8, 1, 15 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Diabetic Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Neuropathy (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionDiabetic Neuropathy - Overview
Diabetic Neuropathy - Therapeutics Development
Diabetic Neuropathy - Therapeutics Assessment
Diabetic Neuropathy - Companies Involved in Therapeutics Development
Diabetic Neuropathy - Drug Profiles
Diabetic Neuropathy - Dormant Projects
Diabetic Neuropathy - Discontinued Products
Diabetic Neuropathy - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Diabetic Neuropathy, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Companies, H2 2020 (Contd..1), H2 2020
- Products under Development by Companies, H2 2020 (Contd..2), H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Target, H2 2020 (Contd..1), H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020 (Contd..1), H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Diabetic Neuropathy - Pipeline by Achelios Therapeutics Inc, H2 2020
- Diabetic Neuropathy - Pipeline by Angelini Group, H2 2020
- Diabetic Neuropathy - Pipeline by Applied Therapeutics Inc, H2 2020
- Diabetic Neuropathy - Pipeline by Bionevia Pharmaceuticals, H2 2020
- Diabetic Neuropathy - Pipeline by Bol Pharma, H2 2020
- Diabetic Neuropathy - Pipeline by Bristol-Myers Squibb Co, H2 2020
- Diabetic Neuropathy - Pipeline by Calchan Ltd, H2 2020
- Diabetic Neuropathy - Pipeline by Celularity Inc, H2 2020
- Diabetic Neuropathy - Pipeline by Commence Bio Inc, H2 2020
- Diabetic Neuropathy - Pipeline by CSPC Pharmaceutical Group Ltd, H2 2020
- Diabetic Neuropathy - Pipeline by Exodos Life Sciences Limited Partnership, H2 2020
- Diabetic Neuropathy - Pipeline by Glycadia Inc, H2 2020
- Diabetic Neuropathy - Pipeline by GNT Pharma Co Ltd, H2 2020
- Diabetic Neuropathy - Pipeline by Grifols SA, H2 2020
- Diabetic Neuropathy - Pipeline by Grunenthal GmbH, H2 2020
- Diabetic Neuropathy - Pipeline by Immune Pharmaceuticals Inc, H2 2020
- Diabetic Neuropathy - Pipeline by Ion Channel Pharmacology LLC, H2 2020
- Diabetic Neuropathy - Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, H2 2020
- Diabetic Neuropathy - Pipeline by Kineta Inc, H2 2020
- Diabetic Neuropathy - Pipeline by Korea United Pharm Inc, H2 2020
- Diabetic Neuropathy - Pipeline by Medifron DBT Co Ltd, H2 2020
- Diabetic Neuropathy - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2020
- Diabetic Neuropathy - Pipeline by Omeros Corp, H2 2020
- Diabetic Neuropathy - Pipeline by Pfizer Inc, H2 2020
- Diabetic Neuropathy - Pipeline by Praetego Inc, H2 2020
- Diabetic Neuropathy - Pipeline by Reata Pharmaceuticals Inc, H2 2020
- Diabetic Neuropathy - Pipeline by Releviate Therapeutics, H2 2020
- Diabetic Neuropathy - Pipeline by Seneca Biopharma Inc, H2 2020
- Diabetic Neuropathy - Pipeline by Sichuan Haisco Pharmaceutical Co Ltd, H2 2020
- Diabetic Neuropathy - Pipeline by Sonnet BioTherapeutics Holdings Inc, H2 2020
- Diabetic Neuropathy - Pipeline by Sphaera Pharma Pte Ltd, H2 2020
- Diabetic Neuropathy - Pipeline by WEX Pharmaceuticals Inc, H2 2020
- Diabetic Neuropathy - Pipeline by Winsantor Inc, H2 2020
- Diabetic Neuropathy - Pipeline by YD Life Science Co, H2 2020
- Diabetic Neuropathy - Pipeline by Zelira Therapeutics Ltd, H2 2020
- Diabetic Neuropathy - Pipeline by Zhejiang Pharmaceutical Co Ltd, H2 2020
- Diabetic Neuropathy - Dormant Projects, H2 2020
- Diabetic Neuropathy - Dormant Projects, H2 2020 (Contd..1), H2 2020
- Diabetic Neuropathy - Dormant Projects, H2 2020 (Contd..2), H2 2020
- Diabetic Neuropathy - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Diabetic Neuropathy, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Achelios Therapeutics Inc
- Angelini Group
- Applied Therapeutics Inc
- Bionevia Pharmaceuticals
- Bol Pharma
- Bristol-Myers Squibb Co
- Calchan Ltd
- Celularity Inc
- Commence Bio Inc
- CSPC Pharmaceutical Group Ltd
- Exodos Life Sciences Limited Partnership
- Glycadia Inc
- GNT Pharma Co Ltd
- Grifols SA
- Grunenthal GmbH
- Immune Pharmaceuticals Inc
- Ion Channel Pharmacology LLC
- Jiangsu Aosaikang Pharmaceutical Co Ltd
- Kineta Inc
- Korea United Pharm Inc
- Medifron DBT Co Ltd
- Mitsubishi Tanabe Pharma Corp
- Omeros Corp
- Pfizer Inc
- Praetego Inc
- Reata Pharmaceuticals Inc
- Releviate Therapeutics
- Seneca Biopharma Inc
- Sichuan Haisco Pharmaceutical Co Ltd
- Sonnet BioTherapeutics Holdings Inc
- Sphaera Pharma Pte Ltd
- WEX Pharmaceuticals Inc
- Winsantor Inc
- YD Life Science Co
- Zelira Therapeutics Ltd
- Zhejiang Pharmaceutical Co Ltd
